In order to address this problem, we here undertook a decision analysis using database the database of 1792 patients with aggressive ATL [3, 6] . Decision analysis is a computerized modeling analysis that can simulate the clinical outcomes of different therapeutic strategies and identify an appropriate therapeutic strategy. This study was approved by the institutional review board of the National Cancer Center, Tokyo, Japan (No. 2014-179). Patients were stratified into the low-, intermediate-, and high-risk groups according to the modified ATL-prognostic index using the prognostic factors, including disease type (acute type), poor performance status, high soluble interleukin-2 receptor level ( > 5000 U/mL), high adjusted calcium level ( ≥ 12 mg/dL), and high C-reactive protein level ( ≥ 2.5 mg/dL) [3] .
We constructed a Markov decision analysis model to compare the outcomes in two therapeutic strategies: chemotherapy followed by up-front allo-HSCT and chemotherapy alone. As shown in Fig. 1a and Supplemental Fig. 1 , all patients were in one of the Markov health states within the model: (1) alive without progressive disease (PD) before HSCT, (2) alive after HSCT before PD, (3) alive after PD before HSCT, (4) alive after HSCT after PD, and (5) dead. The cycle length was 1 month and the analyses were performed for 60 cycles, 5 years. The transition probability in the respective health state was calculated from the underlying hazard of survival of the cohort, using the Kernel density estimation. In terms of the transition probability to receive up-front allo-HSCT, it was set as patients receive up-front allo-HSCT from 2 months following the result of our database. In this model, the transition probability to receive up-front allo-HSCT at 6 months was set as 100% if ATL did not progress before up-front allo-HSCT. Since quality-of-life (QoL) data for patients with aggressive ATL and the incidence of chronic graft-versus-host disease in this database are lacking, estimates of average utility from a similar decision analysis study of patients with acute myeloid leukemia (AML) were used to attempt to adjust for QoL in this study [7] . The distribution of utility was transformed to a β distribution after calculating the mean and standard deviation (SD) using bootstrapping (Supplemental Table 1 ). The model simulated the life expectancy (LE), the quality-adjusted LE (QALE), and survival curve after diagnosis of aggressive ATL. We used the TreeAge Pro 2016 software package (TreeAge Software Inc., Williamstown, MA), Stata version 12 (Stata Corp., College Station, TX) and R (The R Foundation for Statistical Computing, version 3.2.2, Vienna, Austria).
One-and two-way sensitivity analyses were performed to assess the robustness of the decision analysis model for LE or QALE in response to changes in parameters. Plausible range of the utility at each health state was set as the mean ± 2 SD. Probabilistic sensitivity analyses (PSA) using second-order Monte Carlo simulation (n = 1000) were performed to assess the uncertainty in the LE and QALE. The PSA was performed by simultaneously drawing from normal distribution functions for each model parameter according to their means and SDs of 10%.
Patients' characteristics of the data source for the decision analysis model are shown in Supplemental Table 2 . Detailed information was reported previously [3] . In all patients and all risk categories, up-front allo-HSCT was associated with higher LE and QALE in comparison to chemotherapy alone (Table 1) . The estimated survival rates by TreeAge showed the superiority of up-front allo-HSCT (Table 1 and Fig. 1b-e) .
In our current Markov model in which up-front allo-HSCT was performed between 2 and 6 months after diagnosis of ATL, the probability that patients received up-front allo-HSCT before PD was 80, 64 and 47% in the low-, intermediate-and high-risk groups, respectively. We assessed the impact of delay of up-front allo-HSCT on LE by one-way sensitivity analysis. As shown in Supplemental Fig. 2A , in each risk group, delay in up-front allo-HSCT compared with immediate transplantation at the time of diagnosis was associated with loss of LE, which suggested the benefit of early up-front allo-HSCT.
We also assessed the impact of change in the expected overall mortality after up-front allo-HSCT. When the rate of overall mortality after up-front allo-HSCT increased >60% (above 1.6-fold), the optimal treatment strategy changed to chemotherapy alone in terms of LE (Supplemental Fig. 2B ). In each risk groups, the threshold to change the optimal treatment strategy was >20% increase (above 1.2-fold) in the low-risk group, >90% increase (above 1.9-fold) in the intermediate-risk group, and >130% increase (above 2.3-fold) in the high-risk group (Supplemental Fig. 2C-2E ). Twoway sensitivity analysis assessed the change of clinical benefits of treatment strategies as the utility in two health states changed, which represented the change of QoL. In all patients, two-way sensitivity analysis showed that benefits of up-front allo-HSCT did not change across the plausible range of utilities in two health states (Supplemental Fig. 3A ). For patients in the low-risk group, there was uncertainty in the benefit of up-front allo-HSCT if the QoL impairment after allo-HSCT occurred (Supplemental Fig. 3B ). For patients in the intermediate-and high-risk groups, two-way sensitivity analyses showed that benefits of up-front transplantation were robust across the range of plausible utilities in two health states (Supplemental Fig. 3C-3D ). The Monte Carlo simulation showed that the probability of superiority of up-front allo-HSCT was 100% in all patients, 97% in the low-risk group, 100% in the intermediate-risk group, and 100% in the high-risk group in terms of LE, and was 100% in all patients, 75% in the low-risk group, 100% in the intermediate-risk group, and 100% in the high-risk group in terms of QALE.
Our current study demonstrated that chemotherapy followed by up-front allo-HSCT was the optimal treatment strategy in patients with aggressive ATL using a Markov decision analysis. Although a large prospective RCT is the gold standard, it is often difficult in the field of hematological malignancies because of a rarity of the patients or limited realistic treatment option as a comparator. Thus decision analysis was applied to assume the favored treatment strategy in the field of hematological malignancies [7] [8] [9] . Although there was some uncertainty in the benefit of allo-HSCT in the low-risk group, the benefit in the intermediate-and high-risk groups was robust in various sensitivity analyses, which assessed the impact of uncertainty in this model.
When up-front allo-HSCT for aggressive ATL is planned, timing of allo-HSCT and choice of stem cell source can be an important matter to be considered. As one-way sensitivity analyses, which assessed the impact of delay of HSCT on LE, showed that delay of HSCT was consistently associated with loss of expected LE, early allo-HSCT would be preferable. Furthermore, there is a possibility that early application of allo-HSCT itself might improve the clinical outcome by a lower rate of non-relapse mortality as previously reported Decision analysis in aggressive ATL [10] . Based on these data, it would be reasonable to prepare for up-front allo-HSCT as early as possible. In terms of stem cell source, in the one-way sensitivity analyses, which assessed the impact of change in the risk of overall mortality, showed that the threshold to change the optimal treatment strategy was 90% increase (1.9-fold) in the intermediate-risk group and 130% increase (2.3-fold) in the high-risk group. Given the improved clinical outcomes after cord blood stem cell transplant (CBT) or haploidentical transplant recently [11, 12] , CBT or haploidentical transplant could be an appropriate choice as an alternative stem cell source to conduct an upfront allo-HSCT before ATL progresses. The benefits of such strategies incorporating early allo-HSCT including alternative stem cell sources should be confirmed in prospective studies.
The limitations of this study should be clarified. Ideally, all model inputs to build a model for decision analysis should come from high-level evidences such as prospective RCTs, as well as prospective costing and health utility assessments. In our study, all data come from a retrospective study. Furthermore, due to a lack of QoL estimates in patients with aggressive ATL, we used data of patients with AML to calculate QALE. Taking such uncertainty in the parameters into account, we performed several simulations incorporating a wide range of uncertainty in various parameters. In these analyses, the benefit of up-front allo-HSCT was robust for patients in the intermediate-and high-risk groups, which suggests that our results and conclusions could change only if our estimated utilities were dramatically inaccurate.
In conclusion, in the absence of prospective RCTs, our results suggest that up-front allo-HSCT for aggressive ATL is the appropriate treatment strategy in the intermediate-and high-risk groups.
